Pfizer (NYSE:PFE) Issues FY 2026 Earnings Guidance

Pfizer (NYSE:PFE) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of 2.800-3.000 for the period, compared to the consensus EPS estimate of 2.970. The company issued revenue guidance of $59.5 billion-$62.5 billion, compared to the consensus revenue estimate of $61.3 billion.

Pfizer Trading Down 0.6%

Shares of PFE traded down $0.15 during midday trading on Tuesday, hitting $26.16. The stock had a trading volume of 25,990,710 shares, compared to its average volume of 42,534,895. Pfizer has a 1 year low of $21.97 and a 1 year high of $28.75. The firm has a market cap of $148.72 billion, a PE ratio of 19.23 and a beta of 0.35. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. The stock’s 50 day moving average is $27.17 and its 200 day moving average is $26.11.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.71 by $0.04. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The business had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. During the same quarter in the prior year, the firm posted $0.92 earnings per share. The business’s revenue for the quarter was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, analysts forecast that Pfizer will post 2.99 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 8th. This represents a $1.72 annualized dividend and a dividend yield of 6.6%. Pfizer’s dividend payout ratio is currently 126.47%.

Wall Street Analysts Forecast Growth

PFE has been the topic of several recent analyst reports. Zacks Research raised shares of Pfizer from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. Morgan Stanley upped their price target on shares of Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a report on Friday, April 10th. Royal Bank Of Canada restated an “underperform” rating and issued a $25.00 price target on shares of Pfizer in a report on Monday, April 20th. Bank of America dropped their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Thursday, April 9th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and set a $27.00 target price on shares of Pfizer in a report on Wednesday, February 4th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, twelve have assigned a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, Pfizer has a consensus rating of “Hold” and a consensus target price of $28.74.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q1 results topped estimates — Pfizer reported $0.75 EPS (vs. $0.71 consensus) and $14.45B revenue, driven by stronger sales of Eliquis and cancer treatments, showing underlying commercial momentum. Pfizer (PFE) Q1 Earnings and Revenues Top Estimates
• Positive Sentiment: Company press release and deck reaffirm full‑year 2026 outlook while highlighting pipeline progress and recent M&A (obesity/other assets) that support medium‑term growth. Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance (Press Release)
• Positive Sentiment: Major outlets note the beat and attribute strength to non‑COVID portfolio diversification (Eliquis and recent acquisitions), a narrative that supports confidence in near‑term revenue stability. Pfizer beats first-quarter profit estimates on strong demand for blood thinner Eliquis
• Neutral Sentiment: Technical/market context: analysts and technicians are watching chart trendlines after earnings — short‑term technicals may add volatility independent of fundamentals. 2 Trendlines in Focus For Pfizer Stock After Earnings
• Negative Sentiment: Guidance and outlook nuance — FY‑2026 EPS guidance was set at $2.80–$3.00 and revenue at $59.5B–$62.5B, roughly in line but slightly below some consensus points; that tempered the upside from the quarter. PFE Earnings: Pfizer Stock Rises on Q1 Beat despite Lower 2026 Sales Outlook
• Negative Sentiment: Higher R&D spending weighed on profit margins — the company noted increased R&D outlays, which reduced net profit despite revenue growth. That raises near‑term margin pressure and investor concern about spend vs. timing of returns. Pfizer Revenue Rises But Profit Falls Amid Boosted R&D Spending
• Negative Sentiment: Valuation/yield caution — some commentary highlights that the stock’s high dividend yield and long‑term price performance prompt income investors to question growth prospects (sentiment that can pressure the share price if concerns persist). Pfizer Stock: Still Priced Like It’s Dead Money

Institutional Trading of Pfizer

Several hedge funds have recently modified their holdings of the company. Mcguire Capital Advisors Inc. purchased a new stake in shares of Pfizer during the fourth quarter valued at about $64,000. Compound Planning Inc. raised its position in shares of Pfizer by 35.5% in the 4th quarter. Compound Planning Inc. now owns 70,555 shares of the biopharmaceutical company’s stock valued at $1,757,000 after purchasing an additional 18,483 shares during the last quarter. TMB Capital Partners LLC purchased a new position in shares of Pfizer in the 4th quarter valued at approximately $251,000. Axxcess Wealth Management LLC raised its position in shares of Pfizer by 3.3% in the 4th quarter. Axxcess Wealth Management LLC now owns 210,175 shares of the biopharmaceutical company’s stock valued at $5,233,000 after purchasing an additional 6,661 shares during the last quarter. Finally, Birchwood Financial Partners Inc. purchased a new position in shares of Pfizer in the 4th quarter valued at approximately $38,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.